LEXICON PHARMACEUTICALS, INC. Accounts Payable
LEXICON PHARMACEUTICALS, INC. (LXRX) had Accounts Payable of $2.34 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $2.34M.
- 2026-03-31: Accounts Payable, Current $3.00M.
- 2025-12-31: Accounts Payable, Current $3.08M.
- 2025-09-30: Accounts Payable, Current $3.80M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.34M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $3.00M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $3.08M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $3.80M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $5.90M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $10.69M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $14.80M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $14.20M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $12.22M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $8.07M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $14.39M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $12.04M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $10.50M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $10.31M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $10.39M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $9.43M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $7.35M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $9.32M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $9.15M 10-K · filed 2023-03-03 | |
| 2021-09-30 | $8.35M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $8.54M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $4.93M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $5.47M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $11.73M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $29.76M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $18.24M 10-Q · filed 2020-04-27 | |
| 2019-12-31 | $12.18M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $20.91M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $10.03M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $13.87M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $12.05M 10-K · filed 2020-03-12 | $17.76M 10-K · filed 2019-03-15 |
| 2018-09-30 | $51.48M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $50.45M 10-Q · filed 2018-07-30 | |
| 2018-03-31 | $66.55M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $38.76M 10-K · filed 2019-03-15 | $57.65M 10-K · filed 2018-03-01 |
| 2017-09-30 | $52.63M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $43.86M 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $41.95M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $52.88M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $41.55M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $28.23M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $25.54M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $19.73M 10-K · filed 2017-03-06 | |
| 2015-09-30 | $16.36M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $11.29M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $12.14M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $13.06M 10-K · filed 2016-03-11 | |
| 2014-09-30 | $9.74M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $8.35M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $7.07M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $9.71M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $9.71M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $6.28M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $5.44M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $7.66M 10-K · filed 2014-03-07 | |
| 2012-09-30 | $4.31M 10-Q · filed 2012-11-07 | |
| 2012-06-30 | $4.58M 10-Q · filed 2012-08-02 | |
| 2012-03-31 | $5.32M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $6.04M 10-K · filed 2013-03-11 | |
| 2011-09-30 | $5.53M 10-Q · filed 2011-11-01 | |
| 2011-06-30 | $3.67M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $3.16M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |